Valneva (VALN) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Valneva SE has published a study in The British Medical Journal highlighting the severe health and economic impacts of chikungunya, a mosquito-borne disease. The study reveals that between 2011 and 2020, chikungunya caused significant health challenges and an estimated $49.9 billion in economic costs globally. This underscores the need for effective control strategies as the disease continues to spread, exacerbated by climate change.
For further insights into VALN stock, check out TipRanks’ Stock Analysis page.
